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The objective of this study was to compare the efficacy and tolerability of two new antiepileptic drugs, lamotrigine 
(LTG) and vigabatrin (GVG) in everyday clinical practice. A comprehensive retrospective survey of a 
computerized data base and hospital case notes was carried out at the Mersey Regional Epilepsy Clinic (MREC), 
Liverpool, which services a population of 3 million in the North West of England. The study comprised 333 
out-patients with refractory epilepsy exposed to LTG and GVG forming a subset in a total population of 2250 
patients with epilepsy held on a comprehensive database. The main outcome measures were duration of treatment 
with each drug described by a Kaplan-Meier survival curve, seizure control determined by a 50% decrease in 
seizure frequency and freedom from seizures, and incidence of adverse drug effects leading to discontinuation. 
The Kaplan-,Meier curve indicated a 57% probability of patients continuing to take LTG and 43% GVG after 40 
months. A 50% improvement in seizure control followed the addition of LTG in 45% of patients, with 10% seizure 
free, compared with 32% and 6%, respectively after the addition of GVG. LTG was discontinued because of 
adverse events (most frequently skin rash) in 15% of patients compared to GVG in 25% (particularly because of 
personality disturbance and psychiatric disorder). 
Both LTG and GVG are effective new AEDs in patients with refractory epilepsy, treated in a tertiary referral 
out-patient setting. LTG has a broader spectrum of antiepileptic efficacy for patients with both partial and 
idiopathic generalized seizures, whereas GVG should be reserved for patients with partial seizures at low risk of 
psychiatric disorder. 
INTRODUCTION 
New antiepileptic drugs (AEDs) are licensed as a 
result of pre-registration studies which compare a 
potential AED against placebo in add-on clinical 
trialsi4. However, such trials are of limited value 
in informing clinicians about the use of a new 
drug in everyday clinical practice5. Pre- 
registration studies inevitably take place in a 
highly selected population of people with a long 
history of refractory epilepsy, and there must be 
questions about extrapolating results from this 
population to a larger group of less refractory 
patients with less severe epilepsy. Furthermore, 
the studies which will ultimately define the place 
of new AEDs in clinical practice will be 
comparative studies against existing first choice 
drugs. A number of comparative monotherapy 
studies of older drugs have been reported”12. 
These studies are, however, difficult to perform 
and take prolonged periods of time to recruit and 
to analyse. We have adopted a rather different 
approach, namely comprehensive survey of two 
newly licensed AEDs, lamotrigine (LTG) and 
vigabatrin (GVG), within a tertiary referral 
epilepsy centre. 
PATIENTS AND METHODS 
A survey of LTG and GVG treatment was 
performed between September 1993 and Feb- 
ruary 1994 at the Walton Centre for Neurology 
and Neurosurgery. A cohort of 333 patients 
prescribed LTG and GVG was identified from 
the total number of 2250 patients, data of whom 
was held on a computerized data base of the 
Mersey Regional Epilepsy Clinic (MREC) in 
Liverpool, servicing a population of three million 
in the North West of England. The identification 
of patients prescribed LTG and GVG in this 
population was thus comprehensive, all patients 
having their intended AED therapy documented 
on the data base at each visit. We can be 
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confident that all patients in whom there was 
intent to treat with either drug have been 
identified. 
Table 1: Comparison of response-related characteristics of 
oatients treated with LTG and GVG 
A proforma was designed to define demo- 
graphy, epilepsy and seizure type and aetiology, 
pre-existing or associated neurological, intellec- 
tual and psychiatric dysfunction, duration of 
therapy, dosage and concomitant AED therapy, 
adverse effects leading to discontinuation, and 
response of seizure control following treatment 
with LTG or GVG. Seizure control was evaluated 
by estimating the average monthly seizure fre- 
quency over three months before the introduction 
ot LTG or GVG and for the last three months of 
treatment with the maximal dose of each new 
drug. 
Characteristic LTG GVG 
% of patients % of patients 
n=223 n = 217 
Epilepsy severiry 
Severe* 
Number of baseline 
AEDs 
1 
2 
3 
Associated disability 
Neurological dysfunction, 
learning disability and/or 
nsvchiatric disorder 
92 91 
63 62 
36 34 
1 4 
34 37 
Data were initially obtained by viewing the 
computer data base and by perusal of the hospital 
case notes. Subsequently, where data were 
missing, they were retrieved by questioning 
patients, family and general practitioners over the 
telephone. The completed data record forms 
were checked, collated and then entered on a 
computerized data base for further analysis, using 
summary statistics and the construction of a 
Kaplan-Meier survival curve. 
Expressed according to seizure frequency during the three 
months before addition of LTG and GVG, where ‘severe’ 
indicates more than one minor seizure per week or more than 
one major seizure per month. 
RESULTS 
continued in preference to LTG by 17 patients, 
both drugs were continued in combination by 31 
patients and both were discontinued by the same 
patient on 25 occasions. From the Kaplan-Meier 
curve the probability of patients continuing to 
take LTG at 40 months was 57% and that for 
GVG was 43% (Fig. 1). In fact, LTG was still 
being taken by 67% of patients and GVG by 51% 
The population studied was one with severe 
refractory epilepsy typical of that seen in a 
tertiary referral centre. Severe epilepsy, defined 
as more than one minor seizure (not tonic-clonic) 
per week or more than one generalized or 
secondary generalized tonic-clonic seizure per 
month, was present in over 90% of patients 
(Table 1). About two thirds of patients were 
already taking one, a third were taking two, and a 
few three conventional AEDs, while over a third 
had neurological, learning or psychiatric dysfunc- 
tion before LTG or GVG was added to their 
treatment (Table 1). Of the lamotrigine ex- 
posures, 154 (69%) were in patients with localiza- 
tion related epilepsy, 65 (29%) in patients with 
generalized epilepsy, and four in patients whose 
epilepsy was not classifiable. For vigabatrin the 
figures were 182 (83%), 32 (15%) and 3, 
respectively. There were 223 patient-treatments 
with LTG for up to 56 months and 217 
patient-treatments with GVG for up to 72 months 
in 333 patients: 116 patients (35%) were exposed 
to LTG only, 108 patients (32%) to GVG only 
and 109 patients (33%) to both drugs, either 
serially or in combination. LTG was continued in 
preference to GVG by 36 patients and GVG was 
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Fig. 1: Kaplan-Meier survival curve for duration on LTG and 
GVG in 333 patients -, LTG; ---, GVG. 
Number CI-’ Number CI’ 
at at 
risk risk 
LTG GVG 
Immediately before 69 55-70% 93 52-66% 
20 months 
Immediately before 18 44-70% 37 36-52% 
40 months 
CI’, Confidence interval for Kaplan-Meier survival function 
at each time point 
Lamotrigine vs. vigabatrin in everyday clinical practice 
at the time of audit. Both LTG and GVG were 
taken as monotherapy by 12% of patients. The 
addition of LTG was followed by a reduction in 
the number of other AEDs in 37 patients (17%) 
and by GVG in 38 patients (18%). The mean 
number of AEDs before the addition of LTG or 
GVG was 1.5, compared with 1.3 at the census 
point demonstrating that the policy was largely 
one of substituion. A 50% improvement in 
seizure control followed the addition of LTG in 
45% of patients (Fig. 2), with 10% seizure free 
(Fig. 3), compared to 32% (Fig. 2) and 6% (Fig. 
3), respectively for GVG. A 50% seizure 
reduction was recorded in 14 patients following 
substitution of LTG for GVG, in seven patients 
following substitution of GVG for LTG and in 13 
patients who were prescribed LTG and GVG in 
combination. 
LTG was discontinued because of an adverse 
event in 15% of patients, skin rash being the most 
frequent adverse event, accounting for 5% but 
also including nausea, ataxia and visual distur- 
bance (Table 2). GVG was discontinued in 25% 
of patients because of adverse events, including 
personality disturbance, drowsiness and weight 
gain, psychiatric adverse events occurring in 8% 
of patients. The drop out rates due to lack of 
efficacy (as opposed to apparent exacerbation of 
seizures) were 5.5% for LTG and 11% for GVG. 
The median daily dose of LTG was 400 mg. 
without concomitant sodium valproate (VPA) 
and 2000 mg. in combination with VPA while that 
of GVG was 200mg. There was evidence of 
preference for combining LTG with VPA and 
GVG with carbamazepine (CBZ), possibly re- 
lated to the broader spectrum of efficacy observed 
for LTG in both localization-related and general- 
ized epilepsy syndromes. 
3132 
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Fig. 2: Numbers above bars represent those from which % 
responders are calculated. 0, Lamotrigine; n , vigabatrin. 
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Fig. 3: Numbers above bars represent those from which % 
responders are calculated. Cl, Lamotrigine; H, vigabatrin. 
DISCUSSION 
This retrospective survey of the use of two new 
AEDs in a large tertiary referral out-patient 
population with severe epilepsy was non- 
randomized and is therefore subject to potential 
biases which may influence the results’3. A 
selection bias could have occurred since prescri- 
bers clearly stopped exposing patients with 
generalized epilepsies to GVG relatively early in 
the period during which these two drugs became 
available. A further bias was that imposed by the 
earlier availability (by 1 year) of GVG which may 
have resulted in the administration of LTG to a 
more therapeutically refractory patient popula- 
tion. The recording of adverse events in the 
present study was unblinded so that there may 
have been bias in attributing unwanted symptoms 
of specific types to LTG and GVG. 
However, the strength of the study is that it was 
comprehensive and included all patients exposed 
to LTG and GVG within an individual tertiary 
referral centre without any exclusion, the results 
being presented on an intent-to-treat basis. This 
Table 2: Percentage (%) of patients withdrawn due to 
adverse events 
Adverse event % of events leading to withdrawal 
GVG LTG 
n =217 n = 223 
CNS 9 5 
Psychiatric 8 0.5 
Increase in seizures 4 1 
Death 3 1 
Gastro-intestinal 1 2 
Rash 0.5 5 
Total 25 15 
270 
study is not a substitute for randomized con- 
trolled trials of LTG vs. GVG, but it does reflect 
the clinical effectiveness of these two AEDs in the 
real world of treatment of patients with severe 
epilepsy refractory to previous treatment with 
conventional AEDs. It also serves to generate 
hypotheses concerning the use of LTG and GVG 
which can subsequently be tested by prospective 
controlled studies. 
The study was undertaken in a refractory 
population with severe epilepsy as shown by the 
pre-treatment seizure frequency, the high in- 
cidence of associated neurological and intellec- 
tual impairment and by a relatively high mortality 
during follow-up (10 patients died). The retention 
times on both drugs were significant, and the 
mean number of drugs being taken by patients 
fell somewhat, indicating that the drugs appear to 
be clinically useful. 
Patterns of responsiveness and adverse events 
are informative. The results of the present study 
suggest that LTG is as effective as GVG for the 
control of partial seizures, despite the informa- 
tion about responder rates provided by placebo- 
controlled add-on trials’. This result further 
emphasizes that caution needs to be exercised in 
interpreting the results of phase II and III add-on 
trials when comparing new AEDs administered 
to different populations of refractory patients’. 
The results of the present study support a 
different spectrum of efficacy for LTG and GVG. 
They suggest that LTG is a broad-spectrum 
AED, analogous to valproate, effective in pati- 
ents with both localization-related and general- 
ized epilepsy syndromes, whereas GVG should 
be prescribed selectively for patients with 
localization-related epilepsy3. There also appears 
to be a higher incidence of psychiatric side-effects 
leading to discontinuation of GVG than LTG 
and a clearly drug-related excessive incidence 
of skin rash resulting in the withdrawal of 
LTG3. 
G. Schapel 81 D. Chadwick 
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